All
  • All
  • Insight
  • Research Services
  • Preclinical CRO
  • Animal Resource Bank
CN
中文 English

Based on the drug’s mechanism of action, an appropriate animal disease model reflecting the relevant pathogenic pathway is selected, accompanied by a comprehensive suite of diagnostic tools, including pathological, histological, and behavioral assessments.

Based on the drug’s mechanism of action, an appropriate animal disease model reflecting the relevant pathogenic pathway is selected, accompanied by a comprehensive suite of diagnostic tools, including pathological, histological, and behavioral assessments.

Explore more

Effectiveness Evaluation
Psychiatric & neurological disease models

On this page

Publish an article

View more

Effectiveness Evaluation

Based on the drug’s mechanism of action, select an animal disease model that corresponds to the relevant pathogenic mechanism, and concurrently employ a comprehensive suite of complementary assays, including pathological, histological, and behavioral assessments.


I. Service Overview

During the drug development process, evaluating a drug’s efficacy is one of the key determinants of whether it can ultimately be approved for market launch. Efficacy studies encompass both preclinical pharmacodynamic investigations in animal models and clinical efficacy trials in humans. Preclinical pharmacodynamic studies should be tailored to the specific clinical disease and therapeutic context, with appropriate selection of experimental models and methodologies, and designed in accordance with the drug’s classification and its pharmacological mechanisms. For drug development, animal pharmacodynamic studies serve as the foundation for subsequent human clinical trials.


II. Technical Principles and Advantages

Based on the drug’s mechanism of action, select animal disease models that correspond to the relevant pathogenic mechanisms. If the drug’s mechanism is unclear, it is advisable to employ multiple models and diverse methodologies to demonstrate and mutually validate its efficacy, ensuring that the experimental models as closely as possible reflect the intrinsic nature of the clinical pharmacological effects. Over the years, our company has successfully established thousands of animal models, covering the digestive, respiratory, cardiovascular, and nervous systems, as well as oncology, with more than a hundred well‑validated disease models. We also provide a comprehensive suite of complementary assays, including pathological, histological, and behavioral evaluations.


III. Operating Procedure

◆ Develop personalized experimental methodologies for the pharmacological actions of various drugs and design experimental protocols in accordance with relevant national guidelines.
◆ Conduct preliminary experiments to evaluate the drug using animal disease models with different pathogenic mechanisms, as outlined in the protocol, and select the recommended route of administration for clinical use.
◆ Conduct a preliminary evaluation of drug efficacy using pathological, immunological, and behavioral assays.
◆ Conduct large-scale, statistically significant formal experiments on drugs that demonstrated clear efficacy in preliminary studies.
◆ In vitro mechanistic studies: If the drug’s mechanism of action is unclear, in vitro experimental data should be designed to support its efficacy.
◆ Data statistical analysis;
◆ Writing and submitting laboratory reports.


IV. Experimental Service Period

The specific experimental duration should be determined based on the preparation timeline of the animal disease model and the drug intervention schedule.


V. Data Provision
Provides cell images, authentic assay data, and analytical results.